Management of Women with Stage 1 Uterine Papillary Serous Cancer
Author Information
Author(s): Laurie Elit, André LaRoche, Lauren Smith, John Mazurka, Francois Moens, Jan Hauspy, Waldo Jimenez
Primary Institution: McMaster University, Hamilton, ON, Canada
Hypothesis
Is there any adjuvant treatment that could improve or prolong survival for women with surgically staged early disease?
Conclusion
Adjuvant therapy appears to confer benefit in certain groups of women with stage 1 UPSC.
Supporting Evidence
- Women with Stage 1A UPSC with no residual disease may not require adjuvant therapy.
- Adjuvant vault radiation appears to lower recurrence rates.
- Chemotherapy improves survival for women with Stage 1B or 1C disease compared to observation or radiation alone.
Takeaway
Some women with early-stage uterine cancer might not need extra treatment after surgery, while others do benefit from it.
Methodology
A case series from 2008–2010 and a literature review on surgically staged 1 UPSC.
Potential Biases
There is a risk of bias in treatment selection, particularly for women with deeper myometrial involvement.
Limitations
The study relies on retrospective data and small sample sizes, which may introduce bias.
Participant Demographics
Women with surgically staged 1 UPSC, including stages 1A, 1B, and 1C.
Statistical Information
P-Value
0.006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website